Andrea Lantz, MD
Allergy & Immunology · Greenville, SCNPI 1164412318
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 451 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations.
Across 451 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$1K
- Sanofi$1K
- AstraZeneca$1K
- Takeda Pharmaceuticals U.S.A., Inc.$896
- Pfizer$710
- Regeneron Healthcare Solutions, Inc.$526
- plus $3K from 26 others
What the payments were for
- Food & beverage$8,831100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 61 | $1,190 |
| Sanofi | 64 | $1,171 |
| AstraZeneca | 62 | $1,141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $896 |
| Pfizer | 40 | $710 |
| Regeneron Healthcare Solutions, Inc. | 22 | $526 |
| GSK | 27 | $389 |
| AbbVie | 18 | $338 |
| Biocryst US Sales Co., LLC | 13 | $323 |
| Grifols USA, LLC | 13 | $251 |
| Amgen | 12 | $244 |
| Genentech USA, Inc. | 11 | $208 |
| Kaleo, Inc. | 9 | $207 |
| Novartis | 9 | $169 |
| Octapharma USA, Inc. | 4 | $159 |
| Optinose US, Inc. | 9 | $150 |
| Pharming Healthcare, Inc. | 6 | $145 |
| Covis Pharma GmbH | 5 | $82 |
| Bio Products Laboratory USA, Inc. | 4 | $78 |
| LEO Pharma Inc. | 4 | $66 |
| Hospira, Inc. | 3 | $53 |
| Incyte Corporation | 2 | $45 |
| Ionis Pharmaceuticals, Inc. | 2 | $44 |
| Shire North American Group Inc | 3 | $44 |
| Cycle Pharmaceuticals Inc | 2 | $41 |
| Alk-abello, Inc | 2 | $37 |
| Paratek Pharmaceuticals, Inc. | 1 | $33 |
| Lilly USA, LLC | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Gilead | 1 | $19 |
| Biocryst Pharmaceuticals, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $16 |
How this compares
$8,842 in reported general payments places this provider in the 55th percentile of 46 allergy & immunology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 21 | $84,072 |
| Dupixent SyringeDupilumab | 15 | $61,409 |
| Dupixent PenDupilumab | 13 | $50,703 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $41,536 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $20,256 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $9,782 |
| Epinephrine | 40 | $5,717 |
| Azelastine Hcl | 94 | $2,100 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,703 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $1,038 |
| Montelukast Sodium | 123 | $923 |
| Fluticasone Propionate | 42 | $677 |
| Ipratropium Bromide | 38 | $513 |
| Famotidine | 34 | $455 |
| Levocetirizine Dihydrochloride | 12 | $340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $251 | $41,53612 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $389 | $30,03844 claims |
| Hikma Pharmaceuticals USAEpinephrine | $16 | $5,71740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 46 allergy & immunology providers in South Carolina.
Other allergy & immunology in Greenville
- Douglas JohnstonGreenville$329K
- Reid JohnstoneGreenville$13K
- Rudolph JohnstoneGreenville$10K
- Charles GreeneGreenville$9K
- James KuhlenGreenville$8K
- Shiven PatelGreenville$7K
- Dennis PaulkGreenville$5K
- Melissa AndersonGreenville$3K
- John PulciniGreenville$2K
- Erin MullaneyGreenville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.